Testing blood and tissue markers for invasive mucormycosis
Part of Infections clinical trials.
This study looks for specific lab “biomarkers” in people with mucormycosis, a serious fungal infection. It compares results with people who have higher infection risk but no active infection, to help doctors diagnose and track this illness more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 3 to 64 years old (and if you’re a control, you must be 18 to 64).
- You are able to give consent, or (if a child) a parent/guardian can consent and the child can agree too.
- You are being seen or tested at Lille University Hospital.
- You must fit one of these groups: mucormycosis patient, transplant-risk control without infection, or control with certain other specific fungal infections.
- Your diagnosis is based on approved lab/pathology findings (for mucormycosis controls, infection must be ruled out before transplant).
- You do not have a second fungal infection happening at the same time as mucormycosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers samples and data from cancer patients who have certain infections (like mucormycosis or aspergillosis) or are at risk for fungal infections. The goal is to better understand how to diagnose and treat these infections.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This study is testing a new blood or fluid test that may find drug-resistant fungus in people with a weakened immune system who have a serious lung infection. The results could help doctors choose the right medicine faster.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.
This trial tests antifungal drugs in people with a rare but serious fungal infection in the lungs called mucormycosis. It aims to find which treatment works best and is safest for patients.
Hear when a new Mucormycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.